Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
415 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Refractory Multiple Myeloma - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Refractory Multiple Myeloma - Pipeline Review, H1 2015', provides an overview of the Refractory Multiple Myeloma's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Refractory Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Multiple Myeloma and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Refractory Multiple Myeloma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Refractory Multiple Myeloma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Refractory Multiple Myeloma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Refractory Multiple Myeloma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Refractory Multiple Myeloma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Refractory Multiple Myeloma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Refractory Multiple Myeloma Overview 10 Therapeutics Development 11 Pipeline Products for Refractory Multiple Myeloma - Overview 11 Pipeline Products for Refractory Multiple Myeloma - Comparative Analysis 12 Refractory Multiple Myeloma - Therapeutics under Development by Companies 13 Refractory Multiple Myeloma - Therapeutics under Investigation by Universities/Institutes 18 Refractory Multiple Myeloma - Pipeline Products Glance 19 Late Stage Products 19 Clinical Stage Products 20 Early Stage Products 21 Refractory Multiple Myeloma - Products under Development by Companies 22 Refractory Multiple Myeloma - Products under Investigation by Universities/Institutes 27 Refractory Multiple Myeloma - Companies Involved in Therapeutics Development 28 4SC AG 28 AbbVie Inc. 29 Acceleron Pharma, Inc. 30 Acetylon Pharmaceuticals, Inc. 31 Actinium Pharmaceuticals, Inc. 32 Altor BioScience Corporation 33 Arno Therapeutics, Inc. 34 Array BioPharma Inc. 35 Astellas Pharma Inc. 36 Astex Pharmaceuticals, Inc. 37 Biotest AG 38 Bristol-Myers Squibb Company 39 Celgene Corporation 40 Cellectar Biosciences, Inc. 41 Chroma Therapeutics Ltd. 42 CureTech Ltd. 43 Curis, Inc. 44 Dicerna Pharmaceuticals, Inc. 45 Exelixis, Inc. 46 F. Hoffmann-La Roche Ltd. 47 GlaxoSmithKline plc 48 Immunomedics, Inc. 49 Johnson & Johnson 50 Karyopharm Therapeutics, Inc. 51 MedImmune, LLC 52 Merck & Co., Inc. 53 Millennium Pharmaceuticals, Inc. 54 MorphoSys AG 55 Novartis AG 56 Oncolytics Biotech Inc. 57 Oncopeptides AB 58 Onyx Pharmaceuticals, Inc. 59 Patrys Limited 60 Pfizer Inc. 61 Pharma Mar, S.A. 62 Pharmacyclics, Inc. 63 Piramal Enterprises Limited 64 Prolexys Pharmaceuticals, Inc. 65 Sanofi 66 Sevion Therapeutics, Inc. 67 Sigma-Tau S.p.A. 68 Solasia Pharma K.K. 69 Stemline Therapeutics, Inc. 70 Sumitomo Dainippon Pharma Co., Ltd. 71 Synta Pharmaceuticals Corp. 72 Threshold Pharmaceuticals, Inc. 73 Vivolux AB 74 Refractory Multiple Myeloma - Therapeutics Assessment 75 Assessment by Monotherapy Products 75 Assessment by Combination Products 76 Assessment by Target 77 Assessment by Mechanism of Action 81 Assessment by Route of Administration 85 Assessment by Molecule Type 87 Drug Profiles 89 4SC-202 - Drug Profile 89 ACP-196 - Drug Profile 91 afuresertib hydrochloride - Drug Profile 93 alisertib - Drug Profile 95 alpelisib - Drug Profile 99 ALT-801 - Drug Profile 101 amrubicin hydrochloride - Drug Profile 103 AR-42 - Drug Profile 105 AT-7519 - Drug Profile 107 AT-9283 - Drug Profile 110 bendamustine hydrochloride - Drug Profile 112 cabozantinib s-malate - Drug Profile 115 CB-5083 - Drug Profile 118 Cell Therapy to Target CD138 for Relapsed and Refractory Multiple Myeloma - Drug Profile 119 CHR-3996 - Drug Profile 120 CUDC-907 - Drug Profile 121 dalantercept - Drug Profile 123 daratumumab - Drug Profile 125 darinaparsin - Drug Profile 128 dasatinib - Drug Profile 130 DCRM-1711 - Drug Profile 133 DKN-01 - Drug Profile 135 elotuzumab - Drug Profile 137 erismodegib - Drug Profile 139 evofosfamide - Drug Profile 142 filanesib - Drug Profile 149 ganetespib - Drug Profile 151 GSK-2857916 - Drug Profile 156 I131-CLR1404 - Drug Profile 157 ibrutinib - Drug Profile 159 indatuximab ravtansine - Drug Profile 165 ixazomib citrate - Drug Profile 167 LCL-161 - Drug Profile 170 LGH-447 - Drug Profile 172 linsitinib - Drug Profile 173 marizomib - Drug Profile 175 MEDI-551 - Drug Profile 177 Melflufen - Drug Profile 179 milatuzumab - Drug Profile 181 MLN-0128 - Drug Profile 183 Monoclonal Antibody Conjugate to Target CD45 for Oncology - Drug Profile 185 MOR-202 - Drug Profile 186 MV-NIS - Drug Profile 188 oprozomib - Drug Profile 190 P-276 - Drug Profile 192 palbociclib - Drug Profile 194 panobinostat - Drug Profile 198 PAT-SM6 - Drug Profile 204 pelareorep - Drug Profile 206 pembrolizumab - Drug Profile 211 pidilizumab - Drug Profile 215 plerixafor - Drug Profile 217 plitidepsin - Drug Profile 219 pomalidomide - Drug Profile 221 PRLX-93936 - Drug Profile 225 Recombinant Protein for Cancer - Drug Profile 227 ricolinostat - Drug Profile 229 SAR-650984 - Drug Profile 231 selinexor - Drug Profile 233 SL-401 - Drug Profile 237 SNS-01T - Drug Profile 239 SST-0001 - Drug Profile 240 trametinib dimethyl sulfoxide + uprosertib - Drug Profile 241 ulocuplumab - Drug Profile 243 vemurafenib - Drug Profile 245 venetoclax - Drug Profile 248 VLX-1570 - Drug Profile 251 vorinostat - Drug Profile 252 Refractory Multiple Myeloma - Recent Pipeline Updates 256 Refractory Multiple Myeloma - Dormant Projects 394 Refractory Multiple Myeloma - Discontinued Products 398 Refractory Multiple Myeloma - Product Development Milestones 400 Featured News & Press Releases 400 Appendix 409 Methodology 409 Coverage 409 Secondary Research 409 Primary Research 409 Expert Panel Validation 409 Contact Us 409 Disclaimer 410
List of Tables Number of Products under Development for Refractory Multiple Myeloma, H1 2015 16 Number of Products under Development for Refractory Multiple Myeloma - Comparative Analysis, H1 2015 17 Number of Products under Development by Companies, H1 2015 19 Number of Products under Development by Companies, H1 2015 (Contd..1) 20 Number of Products under Development by Companies, H1 2015 (Contd..2) 21 Number of Products under Development by Companies, H1 2015 (Contd..3) 22 Number of Products under Investigation by Universities/Institutes, H1 2015 23 Comparative Analysis by Late Stage Development, H1 2015 24 Comparative Analysis by Clinical Stage Development, H1 2015 25 Comparative Analysis by Early Stage Development, H1 2015 26 Products under Development by Companies, H1 2015 27 Products under Development by Companies, H1 2015 (Contd..1) 28 Products under Development by Companies, H1 2015 (Contd..2) 29 Products under Development by Companies, H1 2015 (Contd..3) 30 Products under Development by Companies, H1 2015 (Contd..4) 31 Products under Investigation by Universities/Institutes, H1 2015 32 Refractory Multiple Myeloma - Pipeline by 4SC AG, H1 2015 33 Refractory Multiple Myeloma - Pipeline by AbbVie Inc., H1 2015 34 Refractory Multiple Myeloma - Pipeline by Acceleron Pharma, Inc., H1 2015 35 Refractory Multiple Myeloma - Pipeline by Acetylon Pharmaceuticals, Inc., H1 2015 36 Refractory Multiple Myeloma - Pipeline by Actinium Pharmaceuticals, Inc., H1 2015 37 Refractory Multiple Myeloma - Pipeline by Altor BioScience Corporation, H1 2015 38 Refractory Multiple Myeloma - Pipeline by Arno Therapeutics, Inc., H1 2015 39 Refractory Multiple Myeloma - Pipeline by Array BioPharma Inc., H1 2015 40 Refractory Multiple Myeloma - Pipeline by Astellas Pharma Inc., H1 2015 41 Refractory Multiple Myeloma - Pipeline by Astex Pharmaceuticals, Inc., H1 2015 42 Refractory Multiple Myeloma - Pipeline by Biotest AG, H1 2015 43 Refractory Multiple Myeloma - Pipeline by Bristol-Myers Squibb Company, H1 2015 44 Refractory Multiple Myeloma - Pipeline by Celgene Corporation, H1 2015 45 Refractory Multiple Myeloma - Pipeline by Cellectar Biosciences, Inc., H1 2015 46 Refractory Multiple Myeloma - Pipeline by Chroma Therapeutics Ltd., H1 2015 47 Refractory Multiple Myeloma - Pipeline by CureTech Ltd., H1 2015 48 Refractory Multiple Myeloma - Pipeline by Curis, Inc., H1 2015 49 Refractory Multiple Myeloma - Pipeline by Dicerna Pharmaceuticals, Inc., H1 2015 50 Refractory Multiple Myeloma - Pipeline by Exelixis, Inc., H1 2015 51 Refractory Multiple Myeloma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 52 Refractory Multiple Myeloma - Pipeline by GlaxoSmithKline plc, H1 2015 53 Refractory Multiple Myeloma - Pipeline by Immunomedics, Inc., H1 2015 54 Refractory Multiple Myeloma - Pipeline by Johnson & Johnson, H1 2015 55 Refractory Multiple Myeloma - Pipeline by Karyopharm Therapeutics, Inc., H1 2015 56 Refractory Multiple Myeloma - Pipeline by MedImmune, LLC, H1 2015 57 Refractory Multiple Myeloma - Pipeline by Merck & Co., Inc., H1 2015 58 Refractory Multiple Myeloma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 59 Refractory Multiple Myeloma - Pipeline by MorphoSys AG, H1 2015 60 Refractory Multiple Myeloma - Pipeline by Novartis AG, H1 2015 61 Refractory Multiple Myeloma - Pipeline by Oncolytics Biotech Inc., H1 2015 62 Refractory Multiple Myeloma - Pipeline by Oncopeptides AB, H1 2015 63 Refractory Multiple Myeloma - Pipeline by Onyx Pharmaceuticals, Inc., H1 2015 64 Refractory Multiple Myeloma - Pipeline by Patrys Limited, H1 2015 65 Refractory Multiple Myeloma - Pipeline by Pfizer Inc., H1 2015 66 Refractory Multiple Myeloma - Pipeline by Pharma Mar, S.A., H1 2015 67 Refractory Multiple Myeloma - Pipeline by Pharmacyclics, Inc., H1 2015 68 Refractory Multiple Myeloma - Pipeline by Piramal Enterprises Limited, H1 2015 69 Refractory Multiple Myeloma - Pipeline by Prolexys Pharmaceuticals, Inc., H1 2015 70 Refractory Multiple Myeloma - Pipeline by Sanofi, H1 2015 71 Refractory Multiple Myeloma - Pipeline by Sevion Therapeutics, Inc., H1 2015 72 Refractory Multiple Myeloma - Pipeline by Sigma-Tau S.p.A., H1 2015 73 Refractory Multiple Myeloma - Pipeline by Solasia Pharma K.K., H1 2015 74 Refractory Multiple Myeloma - Pipeline by Stemline Therapeutics, Inc., H1 2015 75 Refractory Multiple Myeloma - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 76 Refractory Multiple Myeloma - Pipeline by Synta Pharmaceuticals Corp., H1 2015 77 Refractory Multiple Myeloma - Pipeline by Threshold Pharmaceuticals, Inc., H1 2015 78 Refractory Multiple Myeloma - Pipeline by Vivolux AB, H1 2015 79 Assessment by Monotherapy Products, H1 2015 80 Assessment by Combination Products, H1 2015 81 Number of Products by Stage and Target, H1 2015 83 Number of Products by Stage and Mechanism of Action, H1 2015 87 Number of Products by Stage and Route of Administration, H1 2015 91 Number of Products by Stage and Molecule Type, H1 2015 93 Refractory Multiple Myeloma Therapeutics - Recent Pipeline Updates, H1 2015 261 Refractory Multiple Myeloma - Dormant Projects, H1 2015 399 Refractory Multiple Myeloma - Dormant Projects (Contd..1), H1 2015 400 Refractory Multiple Myeloma - Dormant Projects (Contd..2), H1 2015 401 Refractory Multiple Myeloma - Dormant Projects (Contd..3), H1 2015 402 Refractory Multiple Myeloma - Discontinued Products, H1 2015 403 Refractory Multiple Myeloma - Discontinued Products (Contd..1), H1 2015 404
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
